{"id":"aml-y-mg","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to CD28, AML Y mg prevents the interaction between CD28 and its ligands, thereby inhibiting the activation of T-cells. This mechanism of action is thought to reduce inflammation and modulate the immune response.","oneSentence":"AML Y mg is an anti-CD28 monoclonal antibody that inhibits T-cell activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:01:19.054Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of relapsed or refractory follicular lymphoma"}]},"trialDetails":[{"nctId":"NCT05385770","phase":"PHASE3","title":"Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects","status":"COMPLETED","sponsor":"Celltrion","startDate":"2022-07-08","conditions":"Essential Hypertension","enrollment":890},{"nctId":"NCT00618696","phase":"PHASE1","title":"Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-07","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":4}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AML Y mg","genericName":"AML Y mg","companyName":"Celltrion","companyId":"celltrion","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AML Y mg is an anti-CD28 monoclonal antibody that inhibits T-cell activation. Used for Treatment of relapsed or refractory follicular lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}